New shot could help shed pounds – early trial underway

NCT ID NCT06054698

Completed Disease control Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tested an injectable drug called HRS9531 in 61 overweight or obese adults to see if it helps with weight loss over 36 weeks. Participants received either the drug or a placebo, and researchers measured changes in body weight. The goal is to find a new treatment option for obesity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS9531 injection
What this could lead to: If successful, this could point toward a new injectable medication for weight loss in people who are overweight or obese.
What could go wrong: This is an early Phase 2 trial with only 61 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT OR OBESITY

Contacts and locations

Locations

Jinan Central Hospital

Jinan, Shandong, 250013, China
Sir Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310016, China
The Affiliated Hospital of Xuzhou Medicine University

Xuzhou, Jiangsu, 221000, China
Zhejiang Hospital

Hangzhou, Zhejiang, 310007, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.